You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

microsatellite instability (MSI)

Showing 1 - 25 of 1,691
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors Trial (RO7589831)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Aug 16, 2023

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Registry Study in MSI/dMMR Solid Tumors

Not yet recruiting
  • DMMR Cancer
  • +2 more
    • (no location specified)
    Aug 21, 2023

    Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

    Not yet recruiting
    • Multiple Cancer
    • Colorectal Cancer
    • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
    • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
    • (no location specified)
    Aug 20, 2023

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

    Recruiting
    • Colorectal Cancer
    • +3 more
    • Neoadjuvant therapy with PD-L1 inhibitor
    • Guangzhou, Guangdong, China
      the Third Affiliated Hospital of Sun Yat-Sen University
    May 10, 2022

    Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

    Completed
    • Recurrent/Metastatic Gastric Cancer
    • Nivolumab, Paclitaxel
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Sep 9, 2022

    DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Feb 14, 2023

    Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

    Not yet recruiting
    • Melanoma
    • +5 more
    • INCB 99280 with Ipilimumab
    • (no location specified)
    Jun 9, 2023

    Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

    Recruiting
    • Digestive System Cancers
    • Beijing, China
      Peking University Cancer Hospital
    Oct 25, 2023

    MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

    Not yet recruiting
    • MSI-H
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer Trial in Sutton (Avelumab)

    Terminated
    • POLE Exonuclease Mutant Colon Cancer
    • +2 more
    • Sutton, Surrey, United Kingdom
      Royal Marsden NHS Foundation Trust
    Oct 5, 2022

    Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

    Recruiting
    • Colorectal Carcinoma
    • Guangzhou, China
      Sun Yat-sen University
    Dec 29, 2022

    Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

    Recruiting
    • Colorectal Cancer
    • Microsatellite Instability High
    • PD-1 inhibitor plus VEGF inhibitors
    • Guangzhou, Guangdong, China
      651 Dongfeng Road East
    May 27, 2022

    Solid Tumor Trial in Beijing (KN035)

    Recruiting
    • Solid Tumor
    • KN035
    • Beijing, Beijing, China
      Peking University Cancer Hospital, Peking University
    Apr 5, 2022

    MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

    Terminated
    • MSI-H/dMMR Solid Tumor
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Oct 17, 2022

    Localized Oesogastric Adenocarcimona, MSI and or dMMR Trial in France (Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection)

    Recruiting
    • Localized Oesogastric Adenocarcimona
    • MSI and or dMMR
    • Nivolumab 10 MG/ML
    • Ipilimumab 200 MG in 40 ML Injection
    • Besançon, France
    • +14 more
    Jun 10, 2021

    Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer Trial in Boston (Nivolumab, Ipilimumab,

    Recruiting
    • Microsatellite Stable Colorectal Cancer
    • +2 more
    • Boston, Massachusetts
      Massachusetts general Hospital
    Mar 24, 2021

    Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • HX008
    • Investigator's Choice Chemotherapy
    • Hefei, Anhui, China
    • +9 more
    Dec 8, 2022

    Solid Tumors, Identified by NGS, PCR or IHC Trial in United States (Pembrolizumab)

    Recruiting
    • Solid Tumors
    • Identified by NGS, PCR or IHC
    • Basking Ridge, New Jersey
    • +6 more
    Oct 7, 2022

    Colon Cancer Trial (Tislelizumab)

    Not yet recruiting
    • Colon Cancer
    • (no location specified)
    Feb 7, 2022